董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vlad Vitoc | 男 | Co-Founder President, Chief Executive Officer, Chairman of the Board | 52 | 208.46万美元 | 413.80 | 2022-07-27 |
| Steven Chaouki | 男 | Director | 49 | 10.35万美元 | 45.93 | 2022-07-27 |
| Ramiro Guerrero | 男 | Director | 57 | 10.13万美元 | 108.96 | 2022-07-27 |
| Louie Ngar Yee | 女 | Director | 56 | 12.67万美元 | 190.46 | 2022-07-27 |
| Cristian Luput | 男 | Director | 48 | 10.58万美元 | 76.50 | 2022-07-27 |
| Stan Smith | 男 | Director | 75 | 12.31万美元 | 252.67 | 2022-07-27 |
| Laurentiu Vlad | 男 | Director | 47 | 9.12万美元 | 未持股 | 2022-07-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vlad Vitoc | 男 | Co-Founder President, Chief Executive Officer, Chairman of the Board | 52 | 208.46万美元 | 413.80 | 2022-07-27 |
| Sergei M. Gryaznov | -- | Chief Scientific Officer | 62 | 126.73万美元 | 141.15 | 2022-07-27 |
| Mihail Obrocea | 男 | Chief Medical Officer | 63 | 214.60万美元 | 未持股 | 2022-07-27 |
| Joseph F. McGuire | 男 | Chief Financial Officer | 63 | 87.83万美元 | 未持股 | 2022-07-27 |
董事简历
中英对照 | 中文 | 英文- Vlad Vitoc
-
Vlad Vitoc是MAIA Biotechnology, Inc.董事会主席、首席执行官兼总裁。Vitoc博士在商业战略分析和规划以及医疗事务方面拥有广泛的经验，他在其中拥有20年的经验。在此期间，Vitoc博士管理和支持了20多种早期、上市和成熟阶段的化合物，其中包括针对超过25种肿瘤类型的靶向治疗和免疫治疗，包括结直肠癌、肝细胞癌、肺癌、乳腺癌前列腺癌癌症和肾细胞癌。Vlad获得了罗马尼亚Cluj-Napoca医学和药学大学的医学博士学位和南卡罗来纳大学的工商管理硕士学位。
Vlad Vitoc is MAIA Biotechnology, Inc. Chairman of Board, Chief Executive Officer and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina. - Vlad Vitoc是MAIA Biotechnology, Inc.董事会主席、首席执行官兼总裁。Vitoc博士在商业战略分析和规划以及医疗事务方面拥有广泛的经验，他在其中拥有20年的经验。在此期间，Vitoc博士管理和支持了20多种早期、上市和成熟阶段的化合物，其中包括针对超过25种肿瘤类型的靶向治疗和免疫治疗，包括结直肠癌、肝细胞癌、肺癌、乳腺癌前列腺癌癌症和肾细胞癌。Vlad获得了罗马尼亚Cluj-Napoca医学和药学大学的医学博士学位和南卡罗来纳大学的工商管理硕士学位。
- Vlad Vitoc is MAIA Biotechnology, Inc. Chairman of Board, Chief Executive Officer and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.
- Steven Chaouki
-
Steven Chaouki是美国市场和消费者互动总裁，负责监督TransUnion的两条业务线。U.S. Markets为金融服务、保险、公共部门、媒体和多元化市场的商业客户提供信息和见解。Consumer Interactive为消费者提供信用、金融和身份保护服务。此前，他曾担任金融服务执行副总裁，负责公司的金融服务业务，为银行、信用合作社、资本市场、金融服务经销商、汽车贷方和其他客户提供解决方案。在加入TransUnion之前，Chaouki先生曾在汇丰银行担任信用卡/零售服务和汽车金融部门的职务。Chaouki先生获得了芝加哥大学布斯商学院的工商管理硕士学位和波士顿大学的学士学位。
Steven Chaouki is President, U.S. Markets & Consumer Interactive, overseeing two TransUnion business lines. U.S. Markets provides information and insights to business customers across financial services, insurance, public sector, media and diversified markets. Consumer Interactive provides credit, financial and identity protection services to consumers. He previously held the role of Executive Vice President, Financial Services, responsible for the company's financial services business, which provides solutions to banks, credit unions, capital markets, financial services resellers, auto lenders and other customers. Before joining TransUnion, Mr. Chaouki held roles at HSBC in card/retail services and auto finance. Mr. Chaouki earned an M.B.A. from the University of Chicago Booth School of Business and a bachelor's degree from Boston University. - Steven Chaouki是美国市场和消费者互动总裁，负责监督TransUnion的两条业务线。U.S. Markets为金融服务、保险、公共部门、媒体和多元化市场的商业客户提供信息和见解。Consumer Interactive为消费者提供信用、金融和身份保护服务。此前，他曾担任金融服务执行副总裁，负责公司的金融服务业务，为银行、信用合作社、资本市场、金融服务经销商、汽车贷方和其他客户提供解决方案。在加入TransUnion之前，Chaouki先生曾在汇丰银行担任信用卡/零售服务和汽车金融部门的职务。Chaouki先生获得了芝加哥大学布斯商学院的工商管理硕士学位和波士顿大学的学士学位。
- Steven Chaouki is President, U.S. Markets & Consumer Interactive, overseeing two TransUnion business lines. U.S. Markets provides information and insights to business customers across financial services, insurance, public sector, media and diversified markets. Consumer Interactive provides credit, financial and identity protection services to consumers. He previously held the role of Executive Vice President, Financial Services, responsible for the company's financial services business, which provides solutions to banks, credit unions, capital markets, financial services resellers, auto lenders and other customers. Before joining TransUnion, Mr. Chaouki held roles at HSBC in card/retail services and auto finance. Mr. Chaouki earned an M.B.A. from the University of Chicago Booth School of Business and a bachelor's degree from Boston University.
- Ramiro Guerrero
-
Ramiro Guerrero是Imperio，Inc.的创始人兼首席执行官，Imperio，Inc.是一家位于芝加哥和郊区的房地产投资和经纪组织，拥有超过20年的商业经验。在过去的10年中，他还担任风险投资家，帮助企业家和小企业创业。他获得了本科学士学位伊利诺伊大学商业/管理学士学位，墨西哥蒙特雷大都会大学法学博士和法学硕士。得克萨斯州圣安东尼奥圣玛丽大学法学院和奥地利因斯布鲁克大学国际法硕士。
Ramiro Guerrero is the Founder and CEO of IMPERIO, Inc., a Chicago and Suburban based Real Estate Investment and Brokerage Organization with over 20 years of business experience. He has also been a Venture Capitalist for the past 10 years aiding entrepreneurs and small businesses in their startup ventures. He received his undergraduate B.S. degree in Business/Management from the University of Illinois, his J.D. at the Universidad Metropolitana de Monterrey in Monterrey, Mexico and an LL.M. Master of Laws in International Law from St. Mary's University School of Law in San Antonio, Texas and the University of Innsbruck, Austria. - Ramiro Guerrero是Imperio，Inc.的创始人兼首席执行官，Imperio，Inc.是一家位于芝加哥和郊区的房地产投资和经纪组织，拥有超过20年的商业经验。在过去的10年中，他还担任风险投资家，帮助企业家和小企业创业。他获得了本科学士学位伊利诺伊大学商业/管理学士学位，墨西哥蒙特雷大都会大学法学博士和法学硕士。得克萨斯州圣安东尼奥圣玛丽大学法学院和奥地利因斯布鲁克大学国际法硕士。
- Ramiro Guerrero is the Founder and CEO of IMPERIO, Inc., a Chicago and Suburban based Real Estate Investment and Brokerage Organization with over 20 years of business experience. He has also been a Venture Capitalist for the past 10 years aiding entrepreneurs and small businesses in their startup ventures. He received his undergraduate B.S. degree in Business/Management from the University of Illinois, his J.D. at the Universidad Metropolitana de Monterrey in Monterrey, Mexico and an LL.M. Master of Laws in International Law from St. Mary's University School of Law in San Antonio, Texas and the University of Innsbruck, Austria.
- Louie Ngar Yee
-
Louie Ngar Yee在汇丰集团的各种职能部门服务了30年，主要从事全球银行和市场业务，包括投资和证券管理、资产管理和全球研究。她还曾在汇丰银行拉丁美洲、亚太地区和英国的集团内部审计部门担任重要领导职务。Louie女士在香港出生和接受教育，在香港作为执行培训生加入汇丰银行，并于1996年成为汇丰集团的国际经理。从那时起，她在香港、菲律宾、印度尼西亚、台湾、美国、英国和拉丁美洲担任过不同的职务，主要担任关键管理职位，以领导、推动和执行广泛的变革议程管理情况，包括业务再造、业务转型、业务缩减和业务设立。在2020年4月被任命为MAIA Biotechnology之前，Louie女士是汇丰集团集团内部审计的集团首席运营官。
Louie Ngar Yee has 30 years of service with HSBC Group in a variety of functions, principally with businesses of Global Banking and Markets including investment and securities management, asset management, and global research. She also held key leadership positions within Group Internal Audit of HSBC in Latin America, Asia Pacific, and United Kingdom.Born and educated in Hong Kong, Ms. Louie joined HSBC as an executive trainee in Hong Kong and became an International Manager of HSBC Group in 1996. Since then, she has taken up different roles in Hong Kong, the Philippines, Indonesia, Taiwan, the United States, the United Kingdom, and Latin America, primarily in key management positions to lead, drive and execute a change agenda in a wide range of management situations including business re-engineering, business turnaround, business downsizing, and business set up.Prior to her current appointment with MAIA Biotechnology in April 2020 Ms. Louie was the Group Chief Operating Officer of Group Internal Audit of HSBC Group. - Louie Ngar Yee在汇丰集团的各种职能部门服务了30年，主要从事全球银行和市场业务，包括投资和证券管理、资产管理和全球研究。她还曾在汇丰银行拉丁美洲、亚太地区和英国的集团内部审计部门担任重要领导职务。Louie女士在香港出生和接受教育，在香港作为执行培训生加入汇丰银行，并于1996年成为汇丰集团的国际经理。从那时起，她在香港、菲律宾、印度尼西亚、台湾、美国、英国和拉丁美洲担任过不同的职务，主要担任关键管理职位，以领导、推动和执行广泛的变革议程管理情况，包括业务再造、业务转型、业务缩减和业务设立。在2020年4月被任命为MAIA Biotechnology之前，Louie女士是汇丰集团集团内部审计的集团首席运营官。
- Louie Ngar Yee has 30 years of service with HSBC Group in a variety of functions, principally with businesses of Global Banking and Markets including investment and securities management, asset management, and global research. She also held key leadership positions within Group Internal Audit of HSBC in Latin America, Asia Pacific, and United Kingdom.Born and educated in Hong Kong, Ms. Louie joined HSBC as an executive trainee in Hong Kong and became an International Manager of HSBC Group in 1996. Since then, she has taken up different roles in Hong Kong, the Philippines, Indonesia, Taiwan, the United States, the United Kingdom, and Latin America, primarily in key management positions to lead, drive and execute a change agenda in a wide range of management situations including business re-engineering, business turnaround, business downsizing, and business set up.Prior to her current appointment with MAIA Biotechnology in April 2020 Ms. Louie was the Group Chief Operating Officer of Group Internal Audit of HSBC Group.
- Cristian Luput
-
Cristian Luput是Optimus Realty Inc的创始人兼首席执行官，Optimus Realty Inc是一家提供全方位服务的房地产公司，专门从事芝加哥住宅物业的经纪、管理和开发，在房地产领域拥有超过15年的广泛专业知识。Luput先生还成功完成了多项价值数百万美元的房地产合作、合并、并购，他积极参与并在多个慈善组织的董事会任职。Luput先生毕业于罗马尼亚Cluj-Napoca的Babes-Bolyai，主修会计和工商管理。
Cristian Luput is the founder and CEO of Optimus Realty Inc, a full-service real estate company specializing in brokering, managing and developing residential properties in Chicago, with over 15 years of extensive expertise in real estate. Mr. Luput has also successfully completed multiple multimillion dollars real estate partnerships, consolidations, mergers and acquisitions.He is actively involved and serves in the board of directors of several charitable organizations. Mr. Luput is a graduate of Babes-Bolyai, Cluj-Napoca, in Romania with a major in accounting and Business Administration. - Cristian Luput是Optimus Realty Inc的创始人兼首席执行官，Optimus Realty Inc是一家提供全方位服务的房地产公司，专门从事芝加哥住宅物业的经纪、管理和开发，在房地产领域拥有超过15年的广泛专业知识。Luput先生还成功完成了多项价值数百万美元的房地产合作、合并、并购，他积极参与并在多个慈善组织的董事会任职。Luput先生毕业于罗马尼亚Cluj-Napoca的Babes-Bolyai，主修会计和工商管理。
- Cristian Luput is the founder and CEO of Optimus Realty Inc, a full-service real estate company specializing in brokering, managing and developing residential properties in Chicago, with over 15 years of extensive expertise in real estate. Mr. Luput has also successfully completed multiple multimillion dollars real estate partnerships, consolidations, mergers and acquisitions.He is actively involved and serves in the board of directors of several charitable organizations. Mr. Luput is a graduate of Babes-Bolyai, Cluj-Napoca, in Romania with a major in accounting and Business Administration.
- Stan Smith
-
Stan Smith是芝加哥Smith Economics Group，Ltd.的总裁，在全国范围内提供经济和金融咨询。史密斯博士在芝加哥大学接受培训，专攻诉讼经济学，与他人合着了第一本关于经济损失的教科书。史密斯博士曾担任芝加哥大学和德保罗大学法学院的兼职教授，在那里他开设了美国第一门法证经济学课程。
Stan Smith is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics. - Stan Smith是芝加哥Smith Economics Group，Ltd.的总裁，在全国范围内提供经济和金融咨询。史密斯博士在芝加哥大学接受培训，专攻诉讼经济学，与他人合着了第一本关于经济损失的教科书。史密斯博士曾担任芝加哥大学和德保罗大学法学院的兼职教授，在那里他开设了美国第一门法证经济学课程。
- Stan Smith is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics.
- Laurentiu Vlad
-
Laurentiu Vlad是一位非常成功的企业家，他在批发和零售以及照明行业创立并发展了两家成功的公司。他最近的公司Luminii是MAIA Biotechnology公司线性照明领域的市场领导者，已经建设了包括世界贸易中心一号大楼、优步总部、西雅图太空针塔和联合北极星休息室在内的项目。
Laurentiu Vlad is a highly successful entrepreneur has started and grown two successful companies, in wholesale and retail as well as the lighting industry. His most recent company, Luminii, is the MAIA Biotechnology, Inc. market leader in linear lighting, having built projects including One World Trade Center, Uber HQ, Space Needle Seattle, and United Polaris Lounges. - Laurentiu Vlad是一位非常成功的企业家，他在批发和零售以及照明行业创立并发展了两家成功的公司。他最近的公司Luminii是MAIA Biotechnology公司线性照明领域的市场领导者，已经建设了包括世界贸易中心一号大楼、优步总部、西雅图太空针塔和联合北极星休息室在内的项目。
- Laurentiu Vlad is a highly successful entrepreneur has started and grown two successful companies, in wholesale and retail as well as the lighting industry. His most recent company, Luminii, is the MAIA Biotechnology, Inc. market leader in linear lighting, having built projects including One World Trade Center, Uber HQ, Space Needle Seattle, and United Polaris Lounges.
高管简历
中英对照 | 中文 | 英文- Vlad Vitoc
Vlad Vitoc是MAIA Biotechnology, Inc.董事会主席、首席执行官兼总裁。Vitoc博士在商业战略分析和规划以及医疗事务方面拥有广泛的经验，他在其中拥有20年的经验。在此期间，Vitoc博士管理和支持了20多种早期、上市和成熟阶段的化合物，其中包括针对超过25种肿瘤类型的靶向治疗和免疫治疗，包括结直肠癌、肝细胞癌、肺癌、乳腺癌前列腺癌癌症和肾细胞癌。Vlad获得了罗马尼亚Cluj-Napoca医学和药学大学的医学博士学位和南卡罗来纳大学的工商管理硕士学位。
Vlad Vitoc is MAIA Biotechnology, Inc. Chairman of Board, Chief Executive Officer and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.- Vlad Vitoc是MAIA Biotechnology, Inc.董事会主席、首席执行官兼总裁。Vitoc博士在商业战略分析和规划以及医疗事务方面拥有广泛的经验，他在其中拥有20年的经验。在此期间，Vitoc博士管理和支持了20多种早期、上市和成熟阶段的化合物，其中包括针对超过25种肿瘤类型的靶向治疗和免疫治疗，包括结直肠癌、肝细胞癌、肺癌、乳腺癌前列腺癌癌症和肾细胞癌。Vlad获得了罗马尼亚Cluj-Napoca医学和药学大学的医学博士学位和南卡罗来纳大学的工商管理硕士学位。
- Vlad Vitoc is MAIA Biotechnology, Inc. Chairman of Board, Chief Executive Officer and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.
- Sergei M. Gryaznov
Sergei M. Gryaznov是MAIA Biotechnology, Inc.的首席科学官。Gryaznov博士是现代药物发现和开发、肿瘤学、端粒酶、免疫调节疗法、核苷、核苷酸、DNA和RNA类似物、脂质和其他偶联物、小分子和核酸治疗领域的国际公认科学家和专家代理商。Gryaznov博士是一种针对潜在癌症治疗的新型端粒-端粒酶靶向治疗方法的共同发明者，并负责领导表征Thio端粒靶向活性的研究团队，MAIA Biotechnology公司正在开发中的先导化合物。Gryaznov博士以优异的成绩获得了有机化学硕士学位和博士学位。M.V.天然产物化学罗蒙诺索夫莫斯科国立大学。Gryaznov博士还在伊利诺伊州埃文斯顿的西北大学完成了化学博士后奖学金计划。
Sergei M. Gryaznov is MAIA Biotechnology, Inc. Chief Scientific Officer. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules and nucleic acid based therapeutic agents. Dr. Gryaznov is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO's telomere targeting activity, MAIA Biotechnology, Inc. lead compound in development. Dr. Gryaznov obtained a M.S., with Honors, in Organic Chemistry and a Ph.D. in Chemistry of Natural Products from M.V. Lomonosov Moscow State University. Dr. Gryaznov also completed a post-doctoral fellowship program in Chemistry at Northwestern University in Evanston, IL.- Sergei M. Gryaznov是MAIA Biotechnology, Inc.的首席科学官。Gryaznov博士是现代药物发现和开发、肿瘤学、端粒酶、免疫调节疗法、核苷、核苷酸、DNA和RNA类似物、脂质和其他偶联物、小分子和核酸治疗领域的国际公认科学家和专家代理商。Gryaznov博士是一种针对潜在癌症治疗的新型端粒-端粒酶靶向治疗方法的共同发明者，并负责领导表征Thio端粒靶向活性的研究团队，MAIA Biotechnology公司正在开发中的先导化合物。Gryaznov博士以优异的成绩获得了有机化学硕士学位和博士学位。M.V.天然产物化学罗蒙诺索夫莫斯科国立大学。Gryaznov博士还在伊利诺伊州埃文斯顿的西北大学完成了化学博士后奖学金计划。
- Sergei M. Gryaznov is MAIA Biotechnology, Inc. Chief Scientific Officer. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules and nucleic acid based therapeutic agents. Dr. Gryaznov is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO's telomere targeting activity, MAIA Biotechnology, Inc. lead compound in development. Dr. Gryaznov obtained a M.S., with Honors, in Organic Chemistry and a Ph.D. in Chemistry of Natural Products from M.V. Lomonosov Moscow State University. Dr. Gryaznov also completed a post-doctoral fellowship program in Chemistry at Northwestern University in Evanston, IL.
- Mihail Obrocea
Mihail Obrocea是MAIA Biotechnology, Inc.的首席医疗官。Obrocea博士是一名血液学家/肿瘤学家，在学术界和制药/生物技术行业的药物开发方面拥有20多年的经验，在细胞疗法、癌症疫苗、单克隆抗体和小分子的开发方面拥有专业知识。Obrocea博士的研究已发表在肿瘤学同行评审文献中，他与他人合着了与癌症疫苗和免疫学相关的已出版书籍，并在生物技术领域拥有多项专利。Obrocea博士获得了罗马尼亚布加勒斯特Carol Davila医学与药学大学的医学博士学位。
Mihail Obrocea is MAIA Biotechnology, Inc. Chief Medical Officer. Dr. Obrocea is a hematologist/oncologist with over 20 years' experience in drug development in both academia and the pharmaceutical/biotechnology industry with expertise in the development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Dr. Obrocea's research has been published in oncology peer-reviewed literature, he has co-authored published books related to cancer vaccines and immunology, and he holds several patents in the field of biotechnology. Dr. Obrocea received an M.D. from the Carol Davila University of Medicine & Pharmacy in Bucharest, Romania.- Mihail Obrocea是MAIA Biotechnology, Inc.的首席医疗官。Obrocea博士是一名血液学家/肿瘤学家，在学术界和制药/生物技术行业的药物开发方面拥有20多年的经验，在细胞疗法、癌症疫苗、单克隆抗体和小分子的开发方面拥有专业知识。Obrocea博士的研究已发表在肿瘤学同行评审文献中，他与他人合着了与癌症疫苗和免疫学相关的已出版书籍，并在生物技术领域拥有多项专利。Obrocea博士获得了罗马尼亚布加勒斯特Carol Davila医学与药学大学的医学博士学位。
- Mihail Obrocea is MAIA Biotechnology, Inc. Chief Medical Officer. Dr. Obrocea is a hematologist/oncologist with over 20 years' experience in drug development in both academia and the pharmaceutical/biotechnology industry with expertise in the development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Dr. Obrocea's research has been published in oncology peer-reviewed literature, he has co-authored published books related to cancer vaccines and immunology, and he holds several patents in the field of biotechnology. Dr. Obrocea received an M.D. from the Carol Davila University of Medicine & Pharmacy in Bucharest, Romania.
- Joseph F. McGuire
Joseph F. McGuire是MAIA Biotechnology, Inc.的首席财务官，他为Maia带来了30多年的经验，曾在医疗保健、金融服务、投资和制造行业的多家私营和上市公司担任首席财务官。在这些职位上，他的职责包括SEC财务报告、投资者关系、公司治理、法律和审计联络以及团队建设。最近，麦奎尔先生于2014年10月至2021年5月担任Avadim Health, Inc.的首席财务官。Avadim随后根据《美国破产法》第11章提交了一份自愿保护申请，并于2021年8月17日宣布完成其法院批准的将其几乎所有资产出售给一家新成立的公司，并退出第11章规定的重组程序。McGuire先生的职业生涯始于普华永道，在那里他是一名注册会计师，后来在Dean Witter Reynolds和Paine Webber，Inc.担任管理职位。Joe获得了圣母大学的会计学学士学位。
Joseph F. McGuire is MAIA Biotechnology, Inc. Chief Financial Officer. In these roles, his responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. Most recently, Mr. McGuire was the chief financial officer at Avadim Health, Inc. "Avadim" from October 2014 to May 2021. Avadim subsequently filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code and announced on August 17 2021 the completion of its court-approved sale of substantially all of its assets to a newly created company and emergence from the reorganization proceedings under Chapter 11. Mr. McGuire began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Joe received a Bachelor of Science in accounting from the University of Notre Dame.- Joseph F. McGuire是MAIA Biotechnology, Inc.的首席财务官，他为Maia带来了30多年的经验，曾在医疗保健、金融服务、投资和制造行业的多家私营和上市公司担任首席财务官。在这些职位上，他的职责包括SEC财务报告、投资者关系、公司治理、法律和审计联络以及团队建设。最近，麦奎尔先生于2014年10月至2021年5月担任Avadim Health, Inc.的首席财务官。Avadim随后根据《美国破产法》第11章提交了一份自愿保护申请，并于2021年8月17日宣布完成其法院批准的将其几乎所有资产出售给一家新成立的公司，并退出第11章规定的重组程序。McGuire先生的职业生涯始于普华永道，在那里他是一名注册会计师，后来在Dean Witter Reynolds和Paine Webber，Inc.担任管理职位。Joe获得了圣母大学的会计学学士学位。
- Joseph F. McGuire is MAIA Biotechnology, Inc. Chief Financial Officer. In these roles, his responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. Most recently, Mr. McGuire was the chief financial officer at Avadim Health, Inc. "Avadim" from October 2014 to May 2021. Avadim subsequently filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code and announced on August 17 2021 the completion of its court-approved sale of substantially all of its assets to a newly created company and emergence from the reorganization proceedings under Chapter 11. Mr. McGuire began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Joe received a Bachelor of Science in accounting from the University of Notre Dame.